| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Eli Lilly & Co (LLY) has 20 insiders with recent SEC Form 4 filings, including 3 buys and 76 sells. LLY is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| ? | 92.18M | $101.27B | - | |
| CEO | 515.2K | $565.95M | - | |
| VP | 137.5K | $151.03M | - | |
| Dir | 75.1K | $82.50M | - | |
| Dir | 55.5K | $60.94M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 2025 | Lilly Endowment Inc | - | Sell | 112,596 | $821.55 | $92,503,361.30 | - | +31.1% | - | |
| Oct 1, 2025 | Lilly Endowment Inc | - | Sell | 135,193 | $794.15 | $107,363,016.18 | - | +30.8% | - | |
| Oct 1, 2025 | Lilly Endowment Inc | - | Sell | 215,822 | $821.47 | $177,290,448.45 | - | +30.8% | - | |
| Sep 30, 2025 | Lilly Endowment Inc | - | Sell | 113,694 | $763.39 | $86,793,273.90 | - | +41.4% | - | |
| Sep 19, 2025 | Lilly Endowment Inc | - | Sell | 23,665 | $763.10 | $18,058,643.25 | - | +40.5% | - | |
| Sep 18, 2025 | Lilly Endowment Inc | - | Sell | 106,626 | $764.65 | $81,531,958.91 | - | +36.6% | - | |
| Aug 28, 2025 | Zakrowski Donald A | SVP, Finance, &CAO | Sell | 1,000 | $734.93 | $734,930.00 | -20.7% | +50.9% | - | |
| Aug 15, 2025 | Montarce Lucas | EVP &CFO | Buy | 715 | $691.79 | $494,626.99 | +5.1% | +45.9% | - | |
| Aug 13, 2025 | Van Naarden Jacob | EVP &Pres., Lilly Oncology | Buy | 1,000 | $647.36 | $647,360.00 | +5.1% | +49.7% | - | |
| Aug 13, 2025 | Alvarez Ralph | Director | Buy | 758 | $660.25 | $500,472.53 | New | +49.7% | - |